Ahead of the 2024 American Society of Human Genetics annual meeting, Illumina has announced that it will provide updates on its whole-genome sequencing, proteomics, and single-cell technologies alongside data from key opinion leaders. Here’s what attendees can look forward to from the company:
Mapped read technology updates
During the meeting, Steve Barnard, PhD, Illumina’s CTO will provide new details about the company’s constellation mapped read technology. He will be joined by Niall Lennon, PhD, chair and CSO of Broad Clinical Labs, who will present early data on the technology’s flexibility and capabilities.
Illumina’s constellation mapped read technology is designed to streamline whole-genome workflows and eliminate traditional library prep. According to the company, the technology will deliver its most comprehensive whole genome, adding long-range information to its XLEAP-SBS chemistry. The expanded insights will help scientists resolve challenging genic regions such as pseudogenes. They will also be able to generate ultra-long phased data and gain a high-resolution view of complex structural variation.
The company originally announced the constellation mapped read technology in its strategy update in August. The first product based on the technology is set to begin early access in the first half of 2025.
Quantifying proteins
The company will also provide an update on Protein Prep, its solution for sample-to-analysis protein discovery. The solution comes out of Illumina’s partnership with Standard BioTools, formerly SomaLogic, which was initially announced in 2022. During the conference, the company will share data that highlights the solution’s ability to identify and quantify more than 6,000 human proteins as well as its readout compatibility with the NovaSeq X and NovaSeq 6000 systems, which enables multiomics on a single platform.
During the conference, Kamel Lahouel, PhD, assistant professor in the Early Detection and Prevention Division at the Translational Genomics Research Institute (TGen), which is part of City of Hope, will present on a new pilot study that used Protein Prep to investigate the potential of circulating protein concentrations as biomarkers for cancer detection.
TGen is participating in an early access, limited-release program for the solution. When the solution launches in early 2025, Protein Prep will feature 9,000 unique human proteins.
Single-cell sequencing updates
Illumina also plans to showcase PiPseq V, a single-cell analysis solution that came with the company’s acquisition of Fluent BioSciences. The company will discuss how the solution enables researchers to dig deeper into the complexities of cell biology. Presenters will also share early access data and insights from a large study of more than a million neuronal single cells using the technology.
Other news
Illumina will also update attendees on 25B 100-cycle and 200-cycle kits for the NovaSeq X Series, which will be available by the end of the year. The company claims that these kits will be a key enabler of multiomics, allowing customers to perform single-cell, proteomics, and other applications at scale.
The company will also present a series of posters describing studies using the new MiSeq i100 Series instruments. In early October, after weeks of social media teasers, Illumina launched the MiSeq i100 and MiSeq i100 Plus, two new instruments in its portfolio that incorporate the XLEAP-SBS chemistry and DRAGEN data analysis capabilities. At the time of the launch, the company said that the new instruments could be used by researchers in areas such as pathogen detection, analyzing genomic variation in tumors, and researching antimicrobial resistance.
To receive more ASHG news from GEN, including on-the-ground reporting, register for our newsletter here.
